Best of ASCO® Vancouver 2024: Lymphoma – Dr. Diego Villa

Best of ASCO® Vancouver 2024: Lymphoma – Dr. Diego Villa

Best of ASCO® Vancouver 2024
Icon Chair Speaker

Co-Chairs

Dr. Sharlene Gill
Dr. Nancy Nixon

Icon Chair Speaker

Speakers

Dr. Diego Villa

Studies/trials discussed:

  • Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.
  • Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.
  • Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.
  • EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.
Tagged